Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Matthew Kelly to Cilastatin

This is a "connection" page, showing publications Matthew Kelly has written about Cilastatin.

 
Connection Strength
  
 
 
0.054
  
  1. Bradley JS, Makieieva N, T?ndel C, Roilides E, Kelly MS, Patel M, Vaddady P, Maniar A, Zhang Y, Paschke A, Chen LF. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase?1b, Open-Label, Single-Dose Clinical Trial. J Clin Pharmacol. 2023 12; 63(12):1387-1397.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.